medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 1

<< Back Next >>

Ann Hepatol 2011; 10 (1)

The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study

Jáquez QJO, García-Compean D, González GJA, Villarreal PJZ, Lavalle GFJ, Muñoz ELE, López HP, Reyes CE, Redondo VE, Flores RR, Maldonado GH

Language: English
References: 39
Page: 56-62
PDF size: 63.20 Kb.


ABSTRACT

Background. It has been suggested that DM may reduce survival of patients with liver cirrhosis (LC). Nevertheless only few prospective studies assessing the impact of DM on mortality of cirrhotic patients have been published, none in compensated LC. Aims. (i) to study the impact of DM on mortality and (ii) to identify predictors of death. Methods. Patients with compensated LC with and without DM were studied. Survival was analyzed by the Kaplan-Meier Method. Univariate and multivariate analysis was performed to determine independent predictors of mortality. Results. 110 patients were included: 60 without DM and 50 with DM. Diabetic patients had significantly higher frequency of cryptogenic cirrhosis, anemia, hypoalbuminemia, and hypercreatininemia. They also had significantly higher BMI and Child-Pugh score. The 2.5- years cumulative survival was significantly lower in patients with DM (48 vs. 69%, p ‹ 0.05). By univariate analysis: DM, female gender, serum creatinine › 1.5 mg/dL, Child-Pugh score class C and cryptogenic cirrhosis were significant. However, only serum creatinine › 1.5 mg/dL and Child-Pugh score class C were independent predictors of death. Conclusion: DM was associated with a significant increase in mortality in patients with compensated liver cirrhosis. Serum creatinine › 1.5 mg/dL and Child-Pugh score class C were independent predictors of death.


REFERENCES

  1. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-34.

  2. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-43

  3. Picardi A, D’Avola D, Gentilucci UV, Galati G, Fiori E, Spataro S, Afeltra A. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev 2006; 22: 274-83.

  4. Nielsen MF, Caumo A, Aagaard NK, Chandramouli V, Schumann WC, Landau BR, Schmitz O, at al. Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations. Am J Physiol Gastrointest Liver Physiol 2005; 288: 1135-43.

  5. Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990; 8: 29-36.

  6. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-27.

  7. Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998; 28: 141-9.

  8. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822-28.

  9. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-59.

  10. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Blair SN. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care 2000; 23: 18-22.

  11. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-81.

  12. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006; 40: 68-76.

  13. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756-61.

  14. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-25.

  15. Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-48.

  16. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 2005; 22(Suppl. 2): 24-7.

  17. Méndez-Sánchez N, Uribe M: Obesidad. Epidemiología, Fisiopatología y Manifestaciones Clínicas. 1st. Ed. México: El Manual Moderno; 2002.

  18. Tellez-Avila FI, Sanchez-Avila F, Garcia-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda- Contreras E, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14: 4771-5.

  19. Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-5.

  20. American Diabetes Association: Standards of Medical Care in Diabetes-2010. Diabetes Care 2010; 33(Suppl.1): S11-S61.

  21. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh vs MELD. J Hepatol 2005; 42(Suppl. 1): 100-7.

  22. Cox D. Regression models and life tables. J Roy Statist Soc 1972; 34: 187-220.

  23. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-9.

  24. Caldwell SH, Oelsner DH, Iezzoni Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization risk factors for underlying disease. Hepatology 1999; 29: 664-9.

  25. Porepa L, Ray Jg, Sanchez-Romeu P, Boot GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010; 182: 526-31.

  26. Thomas DLM. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.

  27. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Blair SN. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care 2000; 23: 18-22.

  28. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: changing scene. Am J Med 1991; 90: 445-9.

  29. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.

  30. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-80.

  31. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.

  32. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.

  33. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-80.

  34. Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008; 7: 148-51.

  35. Adams LA.Nonalcoholic fatty liver diseases and diabetes mellitus. Endosc Res 2007; 32: 59-69.

  36. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006; 26: 834-9.

  37. Moreau R, Delegue P, Pessione F, Hillaire S, Durand F, Lebrec D, Valla DC. Clinical characteristics and outcome of patients with cirrhosis refractory ascites. Liver Int 2004; 24: 457-64.

  38. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment prophylaxis. J Hepatol 2005; 42(Suppl.): S85-S92.

  39. Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. J Clin Gastroenterol 2007; 41: 403-11.




2020     |     www.medigraphic.com